Stocks
Cara Therapeutics Financial Statements (CARA) |
||||||||||
| Cara Therapeuticssmart-lab.ru | % | 2020 | 2021 | 2022 | 2023 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 25.02.2021 | 01.03.2022 | 06.03.2023 | 31.12.2023 | 06.03.2024 | 14.08.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 135.1 | 23.0 | 41.9 | 21.0 | 21.0 | 9.13 | |||
| Operating Income, bln rub | 5.39 | -89.1 | -87.5 | -121.5 | -121.5 | -108.7 | ||||
| EBITDA, bln rub | ? | 5.59 | -88.2 | -83.8 | -121.5 | -117.7 | -111.0 | |||
| Net profit, bln rub | ? | 8.41 | -88.2 | -83.4 | -118.5 | -118.5 | -115.4 | |||
| OCF, bln rub | ? | -5.49 | -60.1 | -78.7 | -92.1 | -60.3 | ||||
| CAPEX, bln rub | ? | 0.349 | 0.039 | 0.043 | 2.38 | 3.10 | ||||
| FCF, bln rub | ? | -5.84 | -60.1 | -78.8 | -94.5 | -63.4 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 129.7 | 112.1 | 122.1 | 136.3 | 142.5 | 115.8 | ||||
| Cost of production, bln rub | 107.1 | 1.55 | 7.27 | 6.17 | 6.17 | 2.04 | ||||
| R&D, bln rub | 107.9 | 82.7 | 91.9 | 108.5 | 108.5 | 88.0 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 0.604 | 0.604 | 5.10 | ||||
| Assets, bln rub | 271.2 | 247.1 | 182.2 | 125.8 | 125.8 | 72.5 | ||||
| Net Assets, bln rub | ? | 249.0 | 227.5 | 158.8 | 57.1 | 57.1 | 11.6 | |||
| Debt, bln rub | 5.28 | 3.67 | 1.92 | 43.2 | 43.2 | 47.2 | ||||
| Cash, bln rub | 180.9 | 167.0 | 145.4 | 100.8 | 100.8 | 56.6 | ||||
| Net debt, bln rub | -175.7 | -163.4 | -143.5 | -57.6 | -57.6 | -9.45 | ||||
| Ordinary share price, rub | 15.1 | 12.2 | 10.7 | 0.743 | 0.743 | 1.18 | ||||
| Number of ordinary shares, mln | 47.4 | 50.7 | 53.7 | 54.1 | 54.1 | 54.7 | ||||
| Market cap, bln rub | 717 | 618 | 576 | 40 | 40 | 65 | ||||
| EV, bln rub | ? | 542 | 454 | 433 | -17 | -17 | 55 | |||
| Book value, bln rub | 249 | 228 | 159 | 57 | 57 | 12 | ||||
| EPS, rub | ? | 0.18 | -1.74 | -1.55 | -2.19 | -2.19 | -2.11 | |||
| FCF/share, rub | -0.12 | -1.19 | -1.47 | 0.00 | -1.74 | -1.16 | ||||
| BV/share, rub | 5.25 | 4.49 | 2.96 | 1.05 | 1.05 | 0.21 | ||||
| EBITDA margin, % | ? | 4.14% | -383.0% | -200.2% | -579.4% | -561.1% | -1 215% | |||
| Net margin, % | ? | 6.23% | -383.0% | -199.2% | -565.2% | -565.2% | -1 263% | |||
| FCF yield, % | ? | -0.81% | -9.73% | -13.7% | 0.00% | -234.8% | -98.1% | |||
| ROE, % | ? | 3.38% | -38.8% | -52.5% | -207.6% | -207.6% | -994.9% | |||
| ROA, % | ? | 3.10% | -35.7% | -45.8% | -94.2% | -94.2% | -159.2% | |||
| P/E | ? | 85.3 | -7.00 | -6.91 | -0.34 | -0.34 | -0.56 | |||
| P/FCF | -122.9 | -10.3 | -7.32 | -0.43 | -1.02 | |||||
| P/S | ? | 5.31 | 26.8 | 13.8 | 1.92 | 1.92 | 7.07 | |||
| P/BV | ? | 2.88 | 2.72 | 3.63 | 0.70 | 0.70 | 5.57 | |||
| EV/EBITDA | ? | 96.8 | -5.15 | -5.16 | 0.14 | 0.15 | -0.50 | |||
| Debt/EBITDA | -31.4 | 1.85 | 1.71 | 0.47 | 0.49 | 0.09 | ||||
| R&D/CAPEX, % | 30 903% | 212 054% | 213 672% | 4 569% | 2 842% | |||||
| CAPEX/Revenue, % | 0.26% | 0.17% | 0.10% | 0.00% | 11.3% | 33.9% | ||||
| Cara Therapeutics shareholders | ||||||||||
